Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | TLR2 | O60603 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7132449 | 0.99 | KMT2A (0.75) | KMT2AEPHX2TLR2 | |
| SCHEMBL8236471 | 0.96 | KMT2A (0.70) | KMT2AEPHX2 | |
| SCHEMBL793384 | 0.92 | KMT2A (0.85) | KMT2AEPHX2TLR2 | |
| SCHEMBL31419531 | 0.90 | KMT2A (0.66) | KMT2AEPHX2 | |
| SCHEMBL92796 | 0.90 | KMT2A (0.66) | KMT2AEPHX2 | |
| SCHEMBL697928 | 0.89 | KMT2A (0.73) | KMT2AEPHX2 | |
| Hydrochloric Acid SCHEMBL31419532 | 0.89 | KMT2A (0.64) | KMT2AEPHX2TLR2 | |
| SCHEMBL13124061 | 0.88 | KMT2A (0.67) | KMT2AEPHX2TLR2 | |
| SCHEMBL1660910 | 0.88 | KMT2A (0.74) | KMT2AEPHX2 | |
| SCHEMBL17971325 | 0.88 | KMT2A (0.74) | KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3515880-B1 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF ENCODED LIBRARIES | HITGEN INC (CN) | 2023-05-10 | — | — | EP | disclosed |
| WO-2017210288-A1 | ANTIBODY DRUG CONJUGATES HAVING DERIVATIVES OF AMATOXIN AS THE DRUG | SORRENTO THERAPEUTICS, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
| EP-2452679-B1 | TRIPRENYLPHENOLIC CYTOPROTECTIVE AGENT | UNIV TOKYO NAT UNIV CORP (JP) | 2014-05-28 | — | — | EP | disclosed |
| EP-2452679-A1 | CYTOPROTECTIVE AGENT | National University Corporation Tokyo University Of Agriculture and Technology (JP) | 2012-05-16 | — | — | EP | disclosed |
| US-7897721-B2 | Cyclic peptide compositions for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7795378-B2 | Peptide compositions for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100121027-A1 | Cyclic Peptide Compositions for Treatment of Sexual Dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20090253713-A1 | Small Molecule Compositions for Sexual Dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| US-7550602-B1 | Small molecule compositions for sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7473760-B2 | Cyclic peptide compositions for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2009-01-06 | — | — | US | disclosed |
| US-7417027-B2 | Linear and cyclic melanocortin receptor-specific peptides | PALATIN TECHNOLOGIES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-7396814-B2 | Metallopeptide compositions for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-7176279-B2 | Cyclic peptide compositions and methods for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176279-B2 | Cyclic peptide compositions and methods for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253713-A1 | Small Molecule Compositions for Sexual Dysfunction | PDE3B, PDE3A, PDE5A | KMT2A 3461/4885EPHX2 1817/4885TLR2 3878/4885 |
| US-20100121027-A1 | Cyclic Peptide Compositions for Treatment of Sexual Dysfunction | VIP, GNRHR, NPR1 | KMT2A 4341/4885EPHX2 4247/4885TLR2 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.